Journal of Clinical Oncology, Vol 15, 893-900, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

B Jeremic, Y Shibamoto, L Acimovic and S Milisavljevic
Department of Oncology, University Hospital, Kragujevac, Yugoslavia.

PURPOSE: To perform a randomized study of the optimal timing of thoracic radiation (RT) as accelerated hyperfractionated radiation therapy (ACC HFX RT) in combination with concurrent chemotherapy (CHT) in limited-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS: Between 1988 and 1992, 107 patients were enrolled and 103 were assessable. All patients received ACC HFX RT with 1.5 Gy twice daily to 54 Gy plus concurrent daily carboplatin/etoposide (C/E) (30 mg each) and four sequential cycles of cisplatin/etoposide (PE) (30 mg/m2 and 120 mg/m2, respectively, on days 1 to 3). Group I patients (n = 52) received concurrent chemoradiation at weeks 1 to 4, and group II (n = 51) at weeks 6 to 9. Patients who showed a complete response (CR) or partial response (PR) underwent prophylactic cranial irradiation (PCI) at weeks 16 to 17. RESULTS: The median survival time was 34 months in group I and 26 months in group II, and the Kaplan-Meier 5-year survival rates were 30% and 15%, respectively. The difference was almost significant on univariate analysis (P = .052) and was significant on multivariate analysis (P = .027). Group I patients had a significantly higher local control rate than group II patients, but there was no difference between the two groups in distant metastasis rate. There was no difference in the incidence of acute or late grade 3 to 4 toxicity. CONCLUSION: Initial administration of thoracic ACC HFX RT with concurrent C/E seems to produce better local control and survival rates than delayed administration.

This article has been cited by other articles:

				D. J. Samson, J. Seidenfeld, G. R. Simon, A. T. Turrisi III, C. Bonnell, K. M. Ziegler, and N. Aronson Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 314S - 323S. [Abstract] [Full Text] [PDF]

				B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years? Oncologist, September 1, 2007; 12(9): 1096 - 1104. [Abstract] [Full Text] [PDF]

				S. E. Schild, J. A. Bonner, S. Hillman, T. F. Kozelsky, A. P.G. Vigliotti, R. S. Marks, D. L. Graham, G. S. Soori, J. W. Kugler, R. C. Tenglin, et al. Results of a Phase II Study of High-Dose Thoracic Radiation Therapy With Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53) J. Clin. Oncol., July 20, 2007; 25(21): 3124 - 3129. [Abstract] [Full Text] [PDF]

				H. Saito, Y. Takada, Y. Ichinose, K. Eguchi, S. Kudoh, K. Matsui, K. Nakagawa, M. Takada, S. Negoro, K. Tamura, et al. Phase II Study of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902 J. Clin. Oncol., November 20, 2006; 24(33): 5247 - 5252. [Abstract] [Full Text] [PDF]

				S. G. Spiro, L. E. James, R. M. Rudd, C. W. Trask, J. S. Tobias, M. Snee, D. Gilligan, P. A. Murray, M. C. R. de Elvira, K. M. O'Donnell, et al. Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis J. Clin. Oncol., August 20, 2006; 24(24): 3823 - 3830. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, J. Vansteenkiste, A. Kester, I. Rutten, and P. Lambin Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann. Onc., April 1, 2006; 17(4): 543 - 552. [Abstract] [Full Text] [PDF]

				A. M. Brade and I. F. Tannock Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure? J. Clin. Oncol., March 1, 2006; 24(7): 1020 - 1022. [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, S. M. Bentzen, A. Minken, R. Wanders, L. Lutgens, M. Hochstenbag, L. Boersma, B. Wouters, G. Lammering, et al. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1057 - 1063. [Abstract] [Full Text] [PDF]

				B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin/Paclitaxel in Patients With Early-Stage (I/II) Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., October 1, 2005; 23(28): 6873 - 6880. [Abstract] [Full Text] [PDF]

				S. G. Spiro and G. A. Silvestri One Hundred Years of Lung Cancer Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 523 - 529. [Abstract] [Full Text] [PDF]

				K. Kubota, Y. Nishiwaki, T. Sugiura, K. Noda, K. Mori, M. Kawahara, S. Negoro, K. Watanabe, F. Imamura, T. Tamura, et al. Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903 Clin. Cancer Res., August 1, 2005; 11(15): 5534 - 5538. [Abstract] [Full Text] [PDF]

				P. Lorigan, P. J. Woll, M. E. R. O'Brien, L. F. Ashcroft, M. R. Sampson, and N. Thatcher Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer J Natl Cancer Inst, May 4, 2005; 97(9): 666 - 674. [Abstract] [Full Text] [PDF]

				D. B. Fried, D. E. Morris, C. Poole, J. G. Rosenman, J. S. Halle, F. C. Detterbeck, T. A. Hensing, and M. A. Socinski Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2004; 22(23): 4837 - 4845. [Abstract] [Full Text] [PDF]

				M. Huncharek and R. McGarry A Meta-Analysis of the Timing of Chest Irradiation in the Combined Modality Treatment of Limited-Stage Small Cell Lung Cancer Oncologist, November 1, 2004; 9(6): 665 - 672. [Abstract] [Full Text] [PDF]

				B. Jeremic, B. Milicic, A. Dagovic, Z. Vaskovic, and L. Tadic Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., September 1, 2004; 22(17): 3540 - 3548. [Abstract] [Full Text] [PDF]

				S.-H. Lee, Y. C. Ahn, H. J. Kim, D. H. Lim, S. I. Lee, E. Nam, S. H. Park, J. Park, K.-E. Lee, J. O. Park, et al. Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2003; 33(12): 620 - 625. [Abstract] [Full Text] [PDF]

				R Booton, M Jones, and N Thatcher Lung cancer * 7: Management of lung cancer in elderly patients Thorax, August 1, 2003; 58(8): 711 - 720. [Full Text] [PDF]

				G. R. Simon and H. Wagner Small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 259S - 271S. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				M. Machtay The Early Rad Catches the Tumor? J. Clin. Oncol., July 15, 2002; 20(14): 3045 - 3047. [Full Text] [PDF]

				M. Takada, M. Fukuoka, M. Kawahara, T. Sugiura, A. Yokoyama, S. Yokota, Y. Nishiwaki, K. Watanabe, K. Noda, T. Tamura, et al. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104 J. Clin. Oncol., July 15, 2002; 20(14): 3054 - 3060. [Abstract] [Full Text] [PDF]

				J.-H. Lee, J.-H. Lee, J.-H. Ahn, H. Bahng, T.-W. Kim, Y.-K. Kang, K.-H. Lee, J.-C. Kim, C.-S. Yu, J.-H. Kim, et al. Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report J. Clin. Oncol., April 1, 2002; 20(7): 1751 - 1758. [Abstract] [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				B. Glisson, C. Scott, R. Komaki, B. Movsas, and H. Wagner Cisplatin, Ifosfamide, Oral Etoposide, and Concurrent Accelerated Hyperfractionated Thoracic Radiation for Patients With Limited Small-Cell Lung Carcinoma: Results of Radiation Therapy Oncology Group Trial 93-12 J. Clin. Oncol., August 16, 2000; 18(16): 2990 - 2995. [Abstract] [Full Text] [PDF]

				D. H. Johnson Management of Small Cell Lung Cancer* : Current State of the Art Chest, December 1, 1999; 116(suppl_3): 525S - 530S. [Abstract] [Full Text] [PDF]

				B. Jeremic, Y. Shibamoto, N. Nikolic, B. Milicic, S. Milisavljevic, A. Dagovic, J. Aleksandrovic, and G. Radosavljevic-Asic Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer: A Randomized Study J. Clin. Oncol., July 1, 1999; 17(7): 2092 - 2092. [Abstract] [Full Text] [PDF]